Prestige Consumer Healthcare

PBH · NYSE

$49.36−$0.35 (−0.70%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $49.71

PBH analyst rating

HoldConsensus of 3 analysts over the last 12 months. 33% rate it a buy.

Strong buy0
Buy1
Hold2
Underperform0
Sell0

12-month price target · 5 analysts

Average $68.60 (+39.0% upside)

Low: $55.55
Now: $49.36
High: $78.75

Upgrades and downgrades

The latest rating actions, newest first

PBH analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Canaccord Genuity	May 15, 2026	Maintains	Buy	$86.00 → $72.00	42%
Oppenheimer	May 14, 2026	Downgrade	Outperform → Perform	—	66%
Oppenheimer	May 7, 2026	Maintains	Outperform	$77.00 → $65.00	66%
Jefferies	Feb 2, 2026	Maintains	Hold	$70.00 → $66.00	50%
Canaccord Genuity	Nov 7, 2025	Maintains	Buy	$100.00 → $88.00	42%
Jefferies	Oct 27, 2025	Maintains	Hold	$75.00 → $71.00	50%
Oppenheimer	Oct 21, 2025	Maintains	Outperform	$82.00 → $72.00	66%

The case for and against

Updated Sep 5, 2026

Bull case

Prestige Consumer is well-positioned for growth and has a diverse portfolio of leading brands in niche consumer health categories, giving it a competitive edge. The company has a solid track record of generating positive annual free cash flow, with a commitment to reaching <3.0x net debt/adjusted EBITDA by early to mid-2027. While there are potential risks, such as commodity inflation and uncertainties around non-core asset monetizations, Prestige has a strong business model and potential for continued success.

Bear case

Prestige Consumer is facing headwinds in its main market, North America, as it faces increasing competition and pricing pressures. While its portfolio of leading brands in niche categories and recommendations from medical professionals may provide some stability, the company is still heavily reliant on a single geographic region. In addition, its recent acquisition of Clear Eyes may have limited potential for growth. The company's margin expansion is also expected to be slow, and it may face challenges in managing inflation and tariffs in the food production supply chain. The lack of diversity in its executive team is also a concern.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.